Evidence level: B
观察性研究永远分不清”谁影响谁”。降压药是唯一能在人身上做因果的地方——如果两类药降同样多的血压,却让谐波谱朝相反方向变,那就说明谐波谱里确实有一条不属于后负荷的通路。
正文
前面几篇一直在算账:谐波谱的方差有多少归硬化、多少归年龄、多少归疾病。但这些都是观察——血压高的人谐波谱长这样,硬化的人谐波谱长那样。观察到的相关,可能是血压改谐波,也可能是谐波(或者说它背后的血管状态)改血压。
药物能破这个局。给同一批人两种降压力度相同、机制不同的药,看谐波谱是否同步、同向、同幅地变。
第一件事:理想的”纯反射探针”不存在
最常被当成”只改波反射、不动血管”的工具是舌下硝酸甘油。Tahvanainen 等的双盲随机研究(35 名健康人,0.25 mg NTG vs 400 μg 沙丁胺醇吸入)确实显示 NTG 让增强指数下降 7.4%(卧位)到 18.7%(立位),同时脉搏波传导速度也降了(PMID 22179079)。降反射的同时降硬化,两者缠在一起。
更关键的是 Fok 等在 30 例心导管患者里的波强分析(PMID 24516104):NTG 让增强压降了 12.8 mmHg,拆开看——前向波成分降 7.0 mmHg,后向波成分降 5.8 mmHg;且 NTG 完全没有改变后向/前向波的振幅比。也就是说,它降”增强压”的效应里有一大半来自心室射血本身变柔和了,不是外周反射变少了。拿 NTG 当”纯反射开关”是错的——它同时动了三个旋钮:心室射血、波反射、外周阻力。
第二件事:药物类别真的会在谐波谱上分道
真正直接的证据来自动物。Wang 等在正常血压 WKY 大鼠上做自身对照,注射三种降压药后比较血压波形的谐波比例(PMID 22007621):阿替洛尔(β 阻滞剂)显著降低所有阶次的谐波比例;卡托普利(ACEI)和氯沙坦(ARB)显著升高第一和第四谐波比例。
同一个血压下降幅度,方向相反。这是”谐波谱里有一条不属于后负荷的通路”最干净的一条线索——如果谐波谱只是后负荷的换算表,血压降了谱就该朝一个方向走,不该分岔。
第三件事:人体层面,PWV 和 AIx 对药物的响应就是不同步的
三项 meta 分析把这个不同步量化了。Chen 等纳入 10 项 RCT、938 人:ARB 与其他降压药相比,PWV 改善无差异(SMD 0.04,95%CI −0.16~0.24,P=0.71),但增强指数的改善更优(MD 8.94,P=0.01)(PMID 26793356)。Ye 等的 28 篇网络 meta 结论更干脆:八类降压药在 PWV 上没有显著差异,差异只在收缩压(PMID 29960763)。2023 年 RIGIPREV 网络 meta(76 项研究)细分了:用药超过 6 个月时,噻嗪类、ACEI、ARB 及若干联合方案降 PWV 更有优势,而降 AIx 的优势集中在 ACEI 和 ARB(PMID 37724181)。
两个指标分家,说明”硬化”和”反射”在药物作用下不是同一件事。CAFE 研究给了临床侧的印证:2199 名高血压患者,氨氯地平方案与阿替洛尔方案肱动脉收缩压只差 0.7 mmHg(无统计学差异),但中心主动脉收缩压差 4.3 mmHg、中心脉压差 3.0 mmHg,全都显著(PMID 16476843)。手臂上量不出差别,波形上量得出。
第四个坑:β 阻滞剂改的可能只是心率
Casey 等在年轻男女中静脉给普萘洛尔,增强指数升高;但按心率 75 校正后,只有女性仍显著升高,男性的 ΔAIx 与 ΔHR 呈负相关(PMID 22106401)。后来同一组用伊伐布雷定(只降心率、不碰血管)替换 β 阻滞剂做对照:心率、平均动脉压都匹配的情况下,桡动脉增强指数没有变化(PMID 24535377)。也就是说,男性那部分”β 阻滞剂升 AIx”纯粹是心率慢下来的副产品。
而心率慢会让每个心动周期的舒张期变长、反射波落点改变——这恰好会打乱按心率归一化的谐波阶次。任何药物干预的谐波研究,不锁心率就是在测心率。
那怎么做这个分离试验
第一步,四臂平行 + 交叉。 至少四类机制不同的药(ACEI/ARB、CCB、噻嗪、β 阻滞剂)加安慰剂,每臂用药 4 周、洗脱 4 周。要求各臂降压幅度匹配(ΔMAP 组间差 <5 mmHg),否则测到的还是剂量。
第二步,三量同步采集。 每次访视同时测桡动脉压力波形(连续 30 个心动周期取平均)、颈股 PWV、中心动脉压、心率。三量都进模型当协变量,看的是残差谐波谱。
第三步,逐阶方向一致性检验。 对 C1–C10 每一阶,检验四个药物臂的 ΔC 符号是否一致(Kendall W 协调系数)。这是整个设计的分水岭:
- 若四个臂全部同向,且 ΔC 幅度与 ΔMAP 呈线性(R²>0.6)→ 谐波谱就是后负荷的换算表,此前所有”器官共振”解释都要降级;
- 若只在某几阶(预期是 C4)出现方向分岔,且分岔恰好落在”血管扩张类升、β 阻滞剂降”这条线上 → 该阶次携带了独立于后负荷的外周张力/反射信息,共振路径初步成立;
- 若低阶同向、高阶分岔 → 按阶次分层:低阶读后负荷,高阶读共振。
第四步,把心率做成对照臂。 单独加一组伊伐布雷定(只降心率),用它来标定”纯粹由心率变化引起的谐波漂移”是多少。任何药物臂的 ΔC 必须超过这个基线漂移才算数。
三个必须防的坑
别把 NTG 当纯探针。 前向波占它降压效应的一半以上(PMID 24516104),用它推”反射通路”会把心室射血的贡献算进去。
别把降压后的 PWV 下降当”血管软化”。 Stewart 等给高血压患者静脉 NTG,平均动脉压降了 22 mmHg 降到与正常人同一水平,PWV 仍高 24%、颈动脉扩张性仍低 48%(PMID 16908758)。降压撤掉的是”撑”,撤不掉的是”结构”。
别用同类药做跨类别推论。 ARB 在 PWV 上不优于其他药、在 AIx 上更优(PMID 26793356),这两个结论必须分开引用,合起来说”ARB 更好”是超范围。
证据与局限
已验证: 正常血压大鼠中,阿替洛尔降低全部谐波比例、卡托普利与氯沙坦升高 C1 与 C4,同幅度降压下方向相反(PMID 22007621);硝酸甘油降增强压的效应可拆为前向波 7.0 mmHg 与后向波 5.8 mmHg,且不改变后向/前向振幅比(PMID 24516104);NTG 同时降低增强指数与 PWV(PMID 22179079);高血压患者 NTG 急性降压 22 mmHg 后大动脉硬化未恢复(PMID 16908758);三项 meta 一致显示各类降压药在 PWV 上无显著差异、在 AIx 上有类别差异(PMID 26793356、29960763、37724181);CAFE 中肱动脉压相同的两方案中心脉压差 3.0 mmHg(PMID 16476843);β 阻滞剂升高 AIx 的效应在按心率校正后大部分消失,伊伐布雷定替换后 AIx 不变(PMID 22106401、24535377)。
部分验证: “同幅度降压下逐阶谐波谱出现方向分岔”这一命题,目前只有大鼠单点证据(PMID 22007621),人体层面尚无逐阶 C1–C10 的药物对照数据。PWV 与 AIx 分家只能作为间接支持,二者都不是谐波谱本身。
待验证: ① 人体四类降压药在 ΔMAP 匹配条件下,C1–C10 各阶的 ΔC 方向是否分岔;② 分岔是否稳定落在 C4 这一阶(大鼠证据的预测);③ 若所有阶次同向且与 ΔMAP 线性,谐波谱的”共振”解释应如何降级表述。
相关阅读
证据等级: B
参考文献: PMID 22007621, PMID 24516104, PMID 22179079, PMID 16908758, PMID 26793356, PMID 29960763, PMID 37724181, PMID 16476843, PMID 22106401, PMID 24535377
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Treating Antihypertensives as a Single Experiment: Does the Harmonic Spectrum Follow Afterload or Resonance?
Evidence level: B
Observational studies can never distinguish “who affects whom.” Antihypertensive drugs are the only intervention that allows causality in humans—if two drug classes lower blood pressure by the same amount but drive the harmonic spectra in opposite directions, it indicates a pathway within the harmonic spectrum that is not merely a function of afterload.
Main Text
Previous articles have been accounting for the variance: how much belongs to stiffening, how much to age, and how much to disease. But these are all observations—hypertensive patients have such harmonic spectra, stiffening patients have such spectra. Observed correlations could mean blood pressure alters the harmonics, or the harmonics (or the underlying vascular state behind them) alter blood pressure.
Drugs can break this deadlock. Give the same cohort two antihypertensives with identical pressure-lowering effects but different mechanisms, and observe whether the harmonic spectra shift synchronously, in the same direction, and with the same magnitude.
First Point: An Ideal “Pure Reflection Probe” Does Not Exist
The tool most often treated as one that “only alters wave reflection without moving the vessel” is sublingual nitroglycerin. Tahvanainen et al.’s double-blind randomized study (35 healthy individuals, 0.25 mg NTG vs. 400 μg salbutamol inhalation) indeed showed that NTG reduced the augmentation index by 7.4% (supine) to 18.7% (standing), while pulse wave velocity also decreased (PMID 22179079). Reducing reflection while reducing stiffening keeps the two intertwined.
More critically, Fok et al.’s wave intensity analysis in 30 cardiac catheterization patients (PMID 24516104) showed that NTG reduced augmentation pressure by 12.8 mmHg; when decomposed, the forward wave component dropped by 7.0 mmHg and the backward wave component dropped by 5.8 mmHg; furthermore, NTG did not alter the amplitude ratio of backward to forward waves. In other words, a large portion of NTG’s effect on “augmentation pressure” comes from the ventricular ejection itself becoming softer, not from reduced peripheral reflection. Treating NTG as a “pure reflection switch” is incorrect—it simultaneously turns three knobs: ventricular ejection, wave reflection, and peripheral resistance.
Second Point: Drug Classes Truly Diverge on the Harmonic Spectrum
Direct evidence comes from animals. Wang et al., in normotensive WKY rats using a within-subject design, compared harmonic ratios of blood pressure waveforms after injecting three antihypertensives (PMID 22007621): atenolol (β-blocker) significantly reduced harmonic ratios across all orders; captopril (ACEI) and losartan (ARB) significantly increased the first and fourth harmonic ratios.
The same magnitude of blood pressure drop yields opposite directions. This is the cleanest clue yet that “there is a pathway within the harmonic spectrum not belonging to afterload”—if the harmonic spectrum were merely a conversion table for afterload, lowering blood pressure should drive the spectrum in one direction, not diverge.
Third Point: At the Human Level, PWV and AIx Respond Differently to Drugs
Three meta-analyses quantified this desynchronization. Chen et al., including 10 RCTs and 938 individuals, found that compared to other antihypertensives, ARBs showed no difference in PWV improvement (SMD 0.04, 95%CI −0.16~0.24, P=0.71) but superior improvement in augmentation index (MD 8.94, P=0.01) (PMID 26793356). Ye et al.’s network meta-analysis of 28 studies concluded even more decisively: eight classes of antihypertensives showed no significant difference in PWV, with differences only in systolic blood pressure (PMID 29960763). The 2023 RIGIPREV network meta-analysis (76 studies) further subdivided: when medication exceeded 6 months, thiazides, ACEIs, ARBs, and several combination regimens showed advantages in lowering PWV, while advantages in lowering AIx concentrated in ACEIs and ARBs (PMID 37724181).
The two metrics have separated, indicating that “stiffening” and “reflection” are not the same event under drug action. The CAFE study provided clinical corroboration: in 2199 hypertensive patients, the amlodipine regimen and atenolol regimen differed by only 0.7 mmHg in brachial systolic blood pressure (no statistical difference), but differed by 4.3 mmHg in central systolic blood pressure and 3.0 mmHg in central pulse pressure, all significant (PMID 16476843). No difference is measurable on the arm, but it is measurable on the waveform.
Fourth Pitfall: β-Blockers May Only Alter Heart Rate
Casey et al., in young men and women, administered intravenous propranolol; the augmentation index increased; but after correcting for heart rate of 75, only women still showed a significant increase, with men’s ΔAIx negatively correlated with ΔHR (PMID 22106401). Later, the same group used ivabradine (lowering heart rate only, not touching vessels) as a control replacing β-blockers: with matched heart rate and mean arterial pressure, the radial artery augmentation index showed no change (PMID 24535377). In other words, the portion of “β-blockers raising AIx” in men was purely a byproduct of slowing heart rate.
And slowing heart rate lengthens diastole in each cardiac cycle and shifts the landing point of reflection waves—this precisely disrupts harmonic orders normalized by heart rate. Any harmonic study involving drug intervention without locking heart rate is essentially measuring heart rate effects.
So How to Conduct This Separation Experiment
Step 1: Four-Arm Parallel + Crossover. At least four drug classes with different mechanisms (ACEI/ARB, CCB, thiazide, β-blocker) plus placebo, each arm for 4 weeks with a 4-week washout. Require matched blood pressure lowering across arms (ΔMAP group difference <5 mmHg); otherwise, what is measured is simply dose.
Step 2: Synchronous Three-Measurement Collection. At each visit, simultaneously measure radial artery pressure waveform (average of 30 consecutive cardiac cycles), carotid-femoral PWV, central arterial pressure, and heart rate. Enter all three into the model as covariates to examine the residual harmonic spectrum.
Step 3: Order-by-Order Direction Consistency Test. For each order C1–C10, test whether the signs of ΔC are consistent across the four drug arms (Kendall W coefficient). This is the watershed of the entire design:
- If all four arms are uniformly directional, and ΔC magnitude correlates linearly with ΔMAP (R²>0.6) → the harmonic spectrum is merely a conversion table for afterload; all prior “organ resonance” explanations must be downgraded;
- If divergence appears only in specific orders (expected at C4), and the divergence aligns exactly with “vasodilators increase, β-blockers decrease” → that order carries information independent of afterload regarding peripheral tension/reflection; the resonance path is preliminarily established;
- If lower orders are uniform while higher orders diverge → stratify by order: read afterload from lower orders, resonance from higher orders.
Step 4: Add a Heart Rate Control Arm. Specifically add an ivabradine group (lowering heart rate only) to calibrate “pure harmonic drift caused by heart rate changes.” Any ΔC in a drug arm must exceed this baseline drift to be valid.
Three Must-Avoid Pitfalls
Do not treat NTG as a pure probe. The forward wave accounts for more than half of its blood pressure lowering effect (PMID 24516104); using it to infer “reflection pathways” will include ventricular ejection contributions.
Do not treat post-hypertensive PWV reduction as “vascular softening.” Stewart et al., administering IV NTG to hypertensive patients, lowered mean arterial pressure by 22 mmHg to normal levels, yet PWV remained 24% higher and carotid distensibility 48% lower (PMID 16908758). What is withdrawn with blood pressure lowering is the “support”; what cannot be withdrawn is the “structure.”
Do not use cross-class inferences from similar drugs. ARBs are not superior to other drugs in PWV but are superior in AIx (PMID 26793356); these two conclusions must be cited separately; stating “ARB is better” together is out of scope.
Evidence and Limitations
Verified: In normotensive rats, atenolol reduced all harmonic ratios while captopril and losartan increased C1 and C4, showing opposite directions under the same magnitude of blood pressure drop (PMID 22007621); nitroglycerin’s reduction in augmentation pressure can be decomposed into 7.0 mmHg forward wave and 5.8 mmHg backward wave without altering the backward/forward amplitude ratio (PMID 24516104); NTG simultaneously reduced augmentation index and PWV (PMID 22179079); in hypertensive patients, acute NTG-induced blood pressure drop of 22 mmHg did not restore large artery stiffening (PMID 16908758); three meta-analyses consistently showed no significant difference among antihypertensive classes in PWV but category differences in AIx (PMID 26793356, 29960763, 37724181); in CAFE, two regimens with identical brachial pressure differed by 3.0 mmHg in central pulse pressure (PMID 16476843); the effect of β-blockers raising AIx largely disappeared after heart rate correction, and AIx remained unchanged when replaced by ivabradine (PMID 22106401, 24535377).
Partially Verified: The proposition that “harmonic spectra show directional divergence across orders under same-magnitude blood pressure lowering” currently has only single-point evidence from rats (PMID 22007621); no human data exists for drug comparisons across orders C1–C10. The separation of PWV and AIx can only serve as indirect support; neither is the harmonic spectrum itself.
To Be Verified: ① Whether C1–C10 orders show directional divergence under matched ΔMAP conditions across four antihypertensive classes in humans; ② Whether the divergence stabilizes at order C4 (predicted by rat evidence); ③ How to downgrade the “resonance” explanation for the harmonic spectrum if all orders are uniform and linearly correlated with ΔMAP.
Related Reading
- Proportion of Harmonic Changes Explained by “Vascular Stiffening/Afterload” vs. “Organ Resonance”
- Age and Disease Are Two Separate Accounts: Stripping Age from Disease
- Heart Rate Confounding Separation Test
- Environment-Life Frequency Interface Research Pool
Evidence Level: B
References: PMID 22007621, PMID 24516104, PMID 22179079, PMID 16908758, PMID 26793356, PMID 29960763, PMID 37724181, PMID 16476843, PMID 22106401, PMID 24535377
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply